Symposium 20: Pharmacological treatment of the patient with Non-Alcoholic Fatty Disease (NAFLD)
DOI:
https://doi.org/10.47196/diab.v56i3Sup.606Keywords:
diabetes, drugs, treatmentAbstract
EGHNA, has high prevalence and is strongly related to obesity and diabetes, with great impact at the health level since it is one of the largest causes of end-stage liver disease and transplantation.
There are no specific drugs approved for its treatment, only lifestyle changes show benefits: food plan, based on the Mediterranean diet (high in olive oil, fruits, vegetables, legumes, nuts and fish) weight reduction (5-10%) and exercises (aerobic 3 times a week or resistance 2 times a week).
References
-
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
